AP Photo/Alex Brandon
Dr Moncef Slaoui, a former pharma executive, was announced last week as a lead figure in President Donald Trump’s push for a coronavirus vaccine.
Slaoui resigned as a director of the company Moderna — which is trialing one vaccine — to take the position.
However, he continues to hold stock options worth more than $10 million in Moderna, which has seen its stock price skyrocket in recent months.
Moderna’s stock climb was helped by an investment from the federal government, of which Slaoui is now a part.
The holding has been called a potential conflict of interest, as Moderna’s vaccine could be a beneficiary of the program Saloui is leading.
Visit Business Insider’s homepage for more stories.
The former pharma executive tapped by President Donald Trump to lead the federal government’s hunt for a COVID-19 vaccine has more than $10 million in stock options in one of the companies receiving federal funding.
Dr Moncef Slaoui, a Belgian-American, was this week named Chief Scientist for Trump’s “Operation Warp Speed,” which aims to develop a working vaccine as fast as possible.See the rest of the story at Business Insider
Tourist hotspots across England fear they will be swamped with visitors this weekend after Boris Johnson eased the coronavirus lockdownThe UK is set to have at least 95,000 tonnes of unwanted potatoes after the coronavirus lockdown closed fish and chip shopsTrump is blaming China for coronavirus even as he employs the same authoritarian tactics as Xi Jinping
Read more: feedproxy.google.com